代谢异质性影像组学模型预测原发纵隔B细胞淋巴瘤治疗结局
本研究基于IELSG37试验中501例接受利妥昔单抗和多柔比星免疫化疗的原发纵隔B细胞淋巴瘤患者,分析基线PET/CT影像组学特征。在495例可分析患者中提取107个特征,递归分区分类树识别出代谢异质性标志物GLRLM-RV为最强预后特征。低代谢异质性组5年无进展生存率和总生存率显著优于高代谢异质性组,整合GLRLM-RV与TLG的模型预后分层能力优于传统预后指数。
要点
- 基线PET/CT影像组学可预测PMBCL一线治疗结局
- GLRLM-RV低者5年PFS 93% vs 高者65%
- GLRLM-RV联合TLG模型优于IPI等传统指数
核心结论
- 基于代谢异质性的影像组学特征GLRLM-RV可有效预测PMBCL患者的治疗结局,整合GLRLM-RV与TLG的模型预后分层能力优于传统预后指数。
研究设计与样本
- 回顾性分析IELSG37试验中501例接受利妥昔单抗和多柔比星为基础免疫化疗的PMBCL患者的基线PET/CT扫描。
- 采用25% SUVmax分割阈值计算MTV、TLG和代谢异质性等功能参数,在495例患者中提取107个影像组学特征。
- 筛选74个与SUVmax和MTV不相关的特征,使用递归分区分类树方法进行分析。
主要发现
- 递归分区分类树识别出GLRLM-RV(代谢异质性标志物)为最显著的预后特征。
- 低代谢异质性组(GLRLM-RV <0.136)5年无进展生存率为93%,高代谢异质性组为65%(p < 0.0001)。
- 低代谢异质性组5年总生存率为96%,高代谢异质性组为80%(p < 0.0001)。
- 整合GLRLM-RV和TLG的递归分区分类树模型进一步改善PFS和OS的预后分层(p < 0.0001),优于IPI、修订版IPI和年龄调整IPI。
关键数值与推荐
- GLRLM-RV阈值0.136用于区分低代谢异质性与高代谢异质性。
- 影像组学特征提取采用25% SUVmax分割阈值。
- 共提取107个影像组学特征,筛选74个与SUVmax和MTV不相关的特征进行分析。
临床怎么用
- 基线PET/CT影像组学分析可辅助识别PMBCL一线治疗失败高风险患者。
- GLRLM-RV和TLG联合模型可用于预后分层,优于传统IPI等指数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early identification of patients at risk of failing first-line therapy remains a key challenge in primary mediastinal B-cell lymphoma (PMBCL). This study assessed whether positron emission tomography (PET) radiomics could predict treatment outcomes in PMBCL. Baseline PET/computed tomography (CT) scans from 501 patients enrolled in the International Extranodal Lymphoma Study Group 37 (IELSG37) trial and treated with rituximab- and doxorubicin-based immunochemotherapy were analysed. Functional PET parameters reflecting tumour burden (metabolic tumour volume, MTV), glucose consumption (total lesion glycolysis, TLG) and metabolic heterogeneity (MH) were calculated using a 25% maximum standard uptake value (SUVmax) segmentation threshold. Radiomic analysis was performed in 495 patients, extracting 107 features; 74 features uncorrelated with SUVmax and MTV were selected and analysed using a recursive-partitioning classification tree (Ctree) approach. Ctree identified grey-level run-length matrix run variance (GLRLM-RV), a marker of MH, as the most significant prognostic feature. Patients with low MH (GLRLM-RV <0.136) had a 5-year progression-free survival (PFS) of 93%, compared with 65% in those with high MH (p < 0.0001). Five-year overall survival (OS) was 96% vs. 80% respectively (p < 0.0001). A subsequent Ctree model integrating GLRLM-RV and TLG further improved prognostic stratification for PFS and OS (p < 0.0001), outperforming established prognostic indices (International Prognostic Index [IPI], revised-IPI and age-adjusted IPI).
引用
- Ceriani L, Milan L, Cascione L, et al. Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study. Br J Haematol. 2026. PMID: 42304704. doi:10.1111/bjh.70614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。